SCHEMBL9890766

SCHEMBL9890766

NC(=O)Cc1ccc(F)cc1-c1ccc(F)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ICMT O60725 7/20 0.45
GRM2 Q14416 2/20 0.39
MAP4K4 O95819 2/20 0.39
MPO P05164 1/20 0.39
SLC6A4 P31645 1/20 0.39
PTGS1 P23219 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
IKBKB O14920 1/20 0.38
CHUK O15111 1/20 0.38
KCNA5 P22460 1/20 0.38
CDC7 O00311 1/20 0.38
PLK4 O00444 1/20 0.38
DAPK3 O43293 1/20 0.38
PRKD3 O94806 1/20 0.38
CHEK2 O96017 1/20 0.38
CDK1 P06493 1/20 0.38
FES P07332 1/20 0.38
ROS1 P08922 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2394999 0.90 ICMT (0.46) ICMTGRM2PTGS1RAB9AKCNA5
SCHEMBL21875709 0.87 PTGS1 (0.41) ICMTGRM2PTGS1NPC1POLB
SCHEMBL2393249 0.86 ICMT (0.45) ICMTGRM2MAP4K4PTGS1NPC1
SCHEMBL9890764 0.85 ICMT (0.54) ICMTPLK4DAPK3CHEK2CDK1
SCHEMBL16416508 0.85 GCGR (0.45) ICMT
SCHEMBL9890667 0.84 TSHR (0.47) PTGS1
SCHEMBL2395927 0.84 APP (0.42) ICMTMPOSLC6A4
SCHEMBL2392196 0.83 PTGDR2 (0.46) ICMTGRM2SLC6A4PTGS1RAB9A
SCHEMBL9890733 0.81 ICMT (0.44) ICMTMAP4K4
SCHEMBL2395132 0.79 ICMT (0.39) ICMTGRM2MPOSLC6A4MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885GRM2 504/4885MAP4K4 3436/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ICMT 2894/4885GRM2 504/4885MAP4K4 3436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.